April 19, 2021
Selecting a post-PCI antiplatelet regimen based on platelet function or genetic testing seems to improve both efficacy and safety, according to a new meta-analysis. Its authors say the results support the next frontier of personalized medicine despite the lack of randomized trial evidence.
Prior studies, like last year’s TAILOR-PCI, have failed to establish the superiority of a guided antiplatelet strategy over standard therapy, but proponents say no trial so far has been accurately powered to do so.
This 20,000-patient meta-analysis, which combined the TAILOR-PCI, POPular Genetics, TROPICAL-ACS, and PHARMCLO trials, among others, was designed to overcome prior research pitfalls, lead author Mattia Galli, MD (Catholic University of the Sacred Heart, Rome, Italy, and University of Florida College of Medicine, Jacksonville), told TCTMD.